The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Approaching the treatment of R/R myeloma in Brazil: available options and current challenges
Abel Costa, MD, D’or Institute for Research and Education, São Paulo, Brazil, discusses the disparities in access to advanced therapies for patients with multiple myeloma (MM) in Brazil’s dual healthcare system. While the private sector has access to various approved treatments, such as bispecific antibodies and CAR-T, significant delays and challenges remain due to prolonged “brain-to-vein” times and insurance restrictions, often limiting timely treatment of relapsed/refractory (R/R) patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
